Boston Scientific is trading 4.06% down at $49.90, reversing part of its 3.05% gain on August 19, with no clear immediate catalyst identified.
- No new company announcement dated August 20 was identified; the latest official release concerned a September 10 healthcare conference.
- Earlier second-quarter coverage cited reduced 2026 guidance tied to slower WATCHMAN demand and U.S. electrophysiology weakness, but predates today’s move.
- Broader equities are also lower, while healthcare is outperforming overall.